Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update
~ In September 2022, FDA Approved PEDMARK®, the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Tumors ~
Related news for (FENC)
- Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
- Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
- Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany
- Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales
- Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management